Menu
Search
|

Menu

Close
X

Menlo Therapeutics Inc MNLO.OQ (NASDAQ Stock Exchange Global Select Market)

6.97 USD
+0.15 (+2.20%)
As of Nov 16
chart
Previous Close 6.82
Open 6.74
Volume 11,259
3m Avg Volume 47,038
Today’s High 7.03
Today’s Low 6.74
52 Week High 38.68
52 Week Low 5.42
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.20 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
11
FY17
4
FY16
1
EPS (USD)
FY18
-1.644
FY17
-1.539
FY16
-0.376
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
--
15.71
LT Debt to Equity (MRQ)
vs sector
--
11.53
Return on Investment (TTM)
vs sector
--
15.05
Return on Equity (TTM)
vs sector
--
16.62

EXECUTIVE LEADERSHIP

Steven Basta
President, Chief Executive Officer, Director, Since 2018
Salary: $555,900.00
Bonus: $83,400.00
Kristine Ball
Senior Vice President - Corporate Strategy and Chief Financial Officer, Since 2012
Salary: $118,030.00
Bonus: $53,200.00
Paul Kwon
Chief Medical Officer, Since 2016
Salary: $370,000.00
Bonus: $196,500.00
Paul Berns
Independent Director, Since 2017
Salary: --
Bonus: --
Albert Cha
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Cardinal Way Fl 2
REDWOOD CITY   CA   94063-4756

Phone: +1650.4861416

Menlo Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough. The Company’s serlopitant is a small molecule, highly selective NK1-R antagonist. It is developing serlopitant as an once-daily oral tablet therapy. The Company has completed Phase II clinical trials in pruritus associated with atopic dermatitis.

SPONSORED STORIES